P&F Products Expands Cardiovascular Portfolio with AVVie Acquisition

P&F Products Expands Its Cardiovascular Portfolio with AVVie Acquisition

P&F Products & Features GmbH (P&F), a notable player in the medical technology sector, has recently made headlines by acquiring AVVie GmbH. This acquisition was announced on August 5, 2026, in Vienna, and marks a significant step forward in enhancing P&F's portfolio aimed at tackling structural heart diseases.

Founded by renowned cardiac surgeon Professor Werner Mohl, AVVie has developed a groundbreaking transcatheter solution known as the AngelValve™ augmentation system. This product addresses a critical and often unmet need in the treatment of mitral valve insufficiency, a condition affecting more than 13 million people in Europe and the United States. This innovative system presents new options for patients who previously faced limited or no treatment avenues for their condition.

Mitral valve insufficiency occurs when blood flows backward into the heart's left atrium, a serious issue that can lead to various health complications. As alarming as this statistic may be, fewer than 5% of patients suffering from moderate to severe mitral valve disease currently receive appropriate treatment. P&F's mission is clear: they aim to bridge this significant care gap and enhance the quality of life for millions.

The strategic acquisition merges AVVie’s research and development capabilities with P&F’s vast expertise in product development, clinical and regulatory affairs, manufacturing, and marketing. The combination of these assets positions the newly structured company to accelerate innovations in heart disease treatments and reduce development cycles.

Dr. Katharina Kiss, CEO of P&F, stated, “The acquisition of AVVie underscores our ongoing commitment to advancing groundbreaking therapies for structural heart diseases. By integrating AVVie’s technical expertise with P&F’s proficiency in clinical study development and regulatory compliance, we are well-equipped to enhance the AngelValve™ platform and deliver meaningful innovations to physicians and patients globally.”

Furthermore, Siegfried Einhellig, COO and head of R&D at P&F, stressed the importance of this merger, highlighting the unique combination of engineering excellence and proven development capabilities that will significantly benefit the innovation process. He remarked, “We look forward to translating this innovation into a successful therapy.”

While the financial specifics of the acquisition remain undisclosed, the union promises to yield substantial advancements in the field of structural heart therapy. Given that P&F has over 25 years of experience and operations in around 70 countries, this acquisition positions them strongly within the cardiovascular market.

In summary, P&F Products & Features GmbH is poised to redefine the landscape of structural heart disease treatment through its strategic acquisition of AVVie GmbH and the integration of the AngelValve™ augmentation system into its offerings. This merger not only enhances their product lineup but reinforces P&F’s commitment to driving innovation and improving patient outcomes in cardiovascular health.